Viewing Study NCT00001917



Ignite Creation Date: 2024-05-05 @ 11:20 AM
Last Modification Date: 2024-10-26 @ 9:02 AM
Study NCT ID: NCT00001917
Status: COMPLETED
Last Update Posted: 2008-03-04
First Post: 1999-11-03

Brief Title: Brain Imaging in Elderly People and Individuals With Alzheimers Disease
Sponsor: National Institute of Mental Health NIMH
Organization: National Institutes of Health Clinical Center CC

Study Overview

Official Title: M2 Receptor Measurements in Aging and in Alzheimers Disease
Status: COMPLETED
Status Verified Date: 2005-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to use brain imaging technology to study the effects of aging and Alzheimers Disease AD on a specific type of brain receptor

The brain is made up of cells called neurons The neurons communicate with one another and secrete chemicals called neurotransmitters The neurotransmitters bind to specific sites on other neurons called receptors Acetylcholine ACh is a neurotransmitter that binds to ACh receptors In both aging and AD the number of neurons that secrete ACh decreases and the function of some ACh receptors changes This study will use positron emission tomography PET scans of the brain to study the effects of age and AD on muscarinic type 2 M2 a type of ACh receptor

Participants in this study will be injected with a radioactive tracer ligand F-18 FP-TZTP which binds to M2 receptors Participants will then undergo a PET scan in order for the density and function of M2 receptors to be studied
Detailed Description: The Geriatric Psychiatry Branch GPB of the National Institute of Mental Health NIMH proposes to study the effect of aging and Alzheimers Disease AD on muscarinic type 2 M2 receptor density and function using the ligand F-18 FP-TZTP M2 receptors are primarily autoreceptors found on acetylcholine ACh neurons and are lost along with ACh neurons in aging and AD particularly in the cerebral cortex As we near completion of the study of the young versus the old we would like to add a few more healthy subjects to achieve better gender balance continue the accrual of Alzheimers patients and expand the Protocol to include its natural scientific progression Quantification of M2 receptors with a single FP-TZTP scan as we are currently performing with 99-M-0073 provides a measure of the number of cholinergic receptors in the brain but not their capacity to release acetylcholine into the synapse To test this capacity requires a second TZTP scan and the use of an agent that alters acetylcholine concentrations in the synapse Non-human primate studies performed here 1 have found PET scans with FP-TZTP to be sensitive to changes in acetylcholine synapse concentrations as a result of competition in response to the adminstration of the acetylinesterase inhibitor physostigmine We would like to use physostigmine in all groups young older normal and Alzheimers patients to infer differences in capacity to release acetylcholine

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
99-M-0073 None None None